The biotech companies Pelago Bioscience and Biovica have agreed to collaborate in providing a common platform for faster and better evaluation of new oncology candidate drugs and medicines. Together the companies will provide a unique platform, correlating efficacy of novel oncology drugs with mode of action and target interaction evaluation.
This solution offers the opportunity to obtain crucial data earlier in the development of new therapies in the oncology field – information that will be highly valuable for drug developers and accelerate the discovery and development with better and more informed decisions. Pelago Bioscience enables successful drug discovery by providing physiologically relevant high quality target engagement data using the CETSA™ method. Biovica has developed DiviTum™, a highly sensitive assay for measuring cell proliferation rate and prediction & monitoring efficacy of cell cycle regulating oncology drugs. The combined data of in situ target engagement quantification and efficacy measured by impact on cell proliferation will enable a better and more effective evaluation of novel oncology drug candidates in pre-clinical and early clinical studies.
“I believe that the prospect of getting both efficacy information and target engagement measure from the same physiologically relevant sample will be a fantastic advantage for drug developers now and for patients in the near future”, says Michael Dabrowski CEO of Pelago Bioscience. “We are very excited about this opportunity to collaborate with and learn from Biovica as we extend our services towards in vitro diagnostic applications”.
Anders Rylander, CEO at Biovica: “The combination of DiviTum™ and CETSA™ will allow our customers to make important decisions much earlier in the drug development process based on better datasets. We look forward to collaborate with Pelago and bring this concept to drug developers for their benefit. ”
About Pelago Bioscience and CETSA™
Spun out from the Karolinska Institute, Stockholm Sweden, Pelago Bioscience AB was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSA™) for use in determination and quantification of drug–target interactions. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects. This reduces time and money spent on the non-optimal compounds and allows faster development of more efficacious new drugs.
See also www.pelagobio.com
About Biovica and DiviTum™
Biovica is a biotech company focused on improving diagnostics, providing better predictive information and monitoring of patients with cancer. Biovica has developed the, DiviTum™ technology, a highly sensitive assay for measuring cell proliferation rate. DiviTum™ measures an enzyme with a key function in cell proliferation and the rate in which tumour cells grow. DiviTum™ has demonstrated unique values in cancer, predicting therapy efficacy and monitoring the status of the disease and treatment. Biovica is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE labelled and MPA registered.
See also www.biovica.com
Download full Press Release
English version (pdf)
Swedish version (pdf)